Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says

[cafead]

via Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month. Vertex and CRISPR Therapeutics are up first with a Dec. 8 decision deadline on their exa-cel gene therapy, followed by bluebird bio's lovo-cel on Dec. 20.

article source